The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene

A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, and their target gene CCNE2 seems to play an important role in resistance to trastuzumab therapy. Cell viability was evaluated...

Descripción completa

Detalles Bibliográficos
Autores: Tormo, Eduardo, Adam-Artigues, Anna, Ballester, Sandra, Pineda, Begoña, Zazo, Sandra, González-Alonso, Paula, Albanell Mestres, Joan, Rovira Guerín, Ana, Rojo, Federico, Lluch, Ana, Eroles, Pilar
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/34048
Acceso en línea:http://hdl.handle.net/10230/34048
http://dx.doi.org/10.1038/srep41309
Access Level:acceso abierto
Palabra clave:Mama -- Càncer -- Aspectes genètics
Mama -- Càncer -- Tractament
id ES_e6cf74a09db131a4f5d56bee8d078e7d
oai_identifier_str oai:recercat.cat:10230/34048
network_acronym_str ES
network_name_str España
repository_id_str
spelling The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 geneTormo, EduardoAdam-Artigues, AnnaBallester, SandraPineda, BegoñaZazo, SandraGonzález-Alonso, PaulaAlbanell Mestres, JoanRovira Guerín, AnaRojo, FedericoLluch, AnaEroles, PilarMama -- Càncer -- Aspectes genèticsMama -- Càncer -- TractamentA subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, and their target gene CCNE2 seems to play an important role in resistance to trastuzumab therapy. Cell viability was evaluated in trastuzumab treated HER2+ BT474 wt (sensitive), BT474r (acquired resistance), HCC1954 (innate resistance), and MDA-MB-231 (HER2-) cell lines, and the expression of miR-26a, miR-30b, and their target genes was measured. BT474 wt cell viability decreased by 60% and miR-26a and miR-30b were significantly overexpressed (~3-fold, p = 0.003 and p = 0.002, respectively) after trastuzumab treatment, but no differences were observed in resistant and control cell lines. Overexpression of miR-30b sensitized BT474r cells to trastuzumab (p = 0.01) and CCNE2, was significantly overexpressed after trastuzumab treatment in BT474r cells (p = 0.032), but no significant changes were observed in sensitive cell line. When CCNE2 was silenced BT474r cell sensitivity to trastuzumab increased (p = 0.03). Thus, the molecular mechanism of trastuzumab action in BT474 cell line may be regulated by miR-26a and miR-30b and CCNE2 overexpression might play an important role in acquired trastuzumab resistance in HER2+ breast cancer given that resistance was diminished when CCNE2 was silenced.Nature Publishing Group201820182017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/34048http://dx.doi.org/10.1038/srep41309reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésScientific Reports. 2017 Jan 25;7:41309This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/340482026-05-29T05:05:01Z
dc.title.none.fl_str_mv The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
title The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
spellingShingle The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
Tormo, Eduardo
Mama -- Càncer -- Aspectes genètics
Mama -- Càncer -- Tractament
title_short The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
title_full The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
title_fullStr The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
title_full_unstemmed The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
title_sort The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
dc.creator.none.fl_str_mv Tormo, Eduardo
Adam-Artigues, Anna
Ballester, Sandra
Pineda, Begoña
Zazo, Sandra
González-Alonso, Paula
Albanell Mestres, Joan
Rovira Guerín, Ana
Rojo, Federico
Lluch, Ana
Eroles, Pilar
author Tormo, Eduardo
author_facet Tormo, Eduardo
Adam-Artigues, Anna
Ballester, Sandra
Pineda, Begoña
Zazo, Sandra
González-Alonso, Paula
Albanell Mestres, Joan
Rovira Guerín, Ana
Rojo, Federico
Lluch, Ana
Eroles, Pilar
author_role author
author2 Adam-Artigues, Anna
Ballester, Sandra
Pineda, Begoña
Zazo, Sandra
González-Alonso, Paula
Albanell Mestres, Joan
Rovira Guerín, Ana
Rojo, Federico
Lluch, Ana
Eroles, Pilar
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Mama -- Càncer -- Aspectes genètics
Mama -- Càncer -- Tractament
topic Mama -- Càncer -- Aspectes genètics
Mama -- Càncer -- Tractament
description A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, and their target gene CCNE2 seems to play an important role in resistance to trastuzumab therapy. Cell viability was evaluated in trastuzumab treated HER2+ BT474 wt (sensitive), BT474r (acquired resistance), HCC1954 (innate resistance), and MDA-MB-231 (HER2-) cell lines, and the expression of miR-26a, miR-30b, and their target genes was measured. BT474 wt cell viability decreased by 60% and miR-26a and miR-30b were significantly overexpressed (~3-fold, p = 0.003 and p = 0.002, respectively) after trastuzumab treatment, but no differences were observed in resistant and control cell lines. Overexpression of miR-30b sensitized BT474r cells to trastuzumab (p = 0.01) and CCNE2, was significantly overexpressed after trastuzumab treatment in BT474r cells (p = 0.032), but no significant changes were observed in sensitive cell line. When CCNE2 was silenced BT474r cell sensitivity to trastuzumab increased (p = 0.03). Thus, the molecular mechanism of trastuzumab action in BT474 cell line may be regulated by miR-26a and miR-30b and CCNE2 overexpression might play an important role in acquired trastuzumab resistance in HER2+ breast cancer given that resistance was diminished when CCNE2 was silenced.
publishDate 2017
dc.date.none.fl_str_mv 2017
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/34048
http://dx.doi.org/10.1038/srep41309
url http://hdl.handle.net/10230/34048
http://dx.doi.org/10.1038/srep41309
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Scientific Reports. 2017 Jan 25;7:41309
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422799560376320
score 15.812429

Similares en LA Referencia